|
TW438587B
(en)
*
|
1995-06-20 |
2001-06-07 |
Takeda Chemical Industries Ltd |
A pharmaceutical composition for prophylaxis and treatment of diabetes
|
|
US5859037A
(en)
*
|
1997-02-19 |
1999-01-12 |
Warner-Lambert Company |
Sulfonylurea-glitazone combinations for diabetes
|
|
PL195140B1
(pl)
*
|
1997-06-18 |
2007-08-31 |
Smithkline Beecham Plc |
Kompozycja farmaceutyczna zawierająca 5-[4-[2-(N-metylo-N-(2-pirydylo)amino)etoksy]-benzylo] tiazolidyno-2,4-dion i jej zastosowanie
|
|
US20020004515A1
(en)
*
|
1997-06-18 |
2002-01-10 |
Smith Stephen Alistair |
Treatment of diabetes with thiazolidinedione and metformin
|
|
US20010049380A1
(en)
*
|
1997-06-18 |
2001-12-06 |
Smith Stephen Alistair |
Treatment of diabetes with thiazolidinedione and sulphonylurea
|
|
PL198018B1
(pl)
*
|
1997-06-18 |
2008-05-30 |
Smithkline Beecham Plc |
Kompozycja farmaceutyczna przeciwcukrzycowa zawierająca sulfonylomocznik i tiazolidynodion i jej zastosowanie
|
|
GB9715306D0
(en)
*
|
1997-07-18 |
1997-09-24 |
Smithkline Beecham Plc |
Novel method of treatment
|
|
US6099859A
(en)
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
|
US7105552B2
(en)
|
1998-05-08 |
2006-09-12 |
Theracos, Inc. |
Heterocyclic analogs of diphenylethylene compounds
|
|
EP1087963B1
(en)
|
1998-06-19 |
2004-08-25 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
US7045519B2
(en)
*
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
|
US20030153607A1
(en)
*
|
1998-11-12 |
2003-08-14 |
Smithkline Beecham P.L.C. |
Novel composition and use
|
|
GB9824893D0
(en)
*
|
1998-11-12 |
1999-01-06 |
Smithkline Beckman Corp |
Novel method of treatment
|
|
US20040081697A1
(en)
*
|
1998-11-12 |
2004-04-29 |
Smithkline Beecham P.L.C. |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
|
US20040102486A1
(en)
*
|
1998-11-12 |
2004-05-27 |
Smithkline Beecham Corporation |
Novel method of treatment
|
|
NZ512219A
(en)
*
|
1998-12-24 |
2004-12-24 |
Metabasis Therapeutics Inc |
A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
|
|
US7001746B1
(en)
*
|
1999-01-29 |
2006-02-21 |
Artecel Sciences, Inc. |
Methods and compositions for the differentiation of human preadipocytes into adipocytes
|
|
US6617122B1
(en)
*
|
1999-03-15 |
2003-09-09 |
Xenon Genetics, Inc. |
Process for identifying modulators of ABC1 activity
|
|
US7407978B2
(en)
*
|
1999-04-06 |
2008-08-05 |
Theracos, Inc. |
Heterocyclic analogs of diphenylethylene compounds
|
|
US20060154864A1
(en)
*
|
1999-11-01 |
2006-07-13 |
Emory University |
Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
|
|
US7563775B2
(en)
*
|
2000-11-01 |
2009-07-21 |
Betty C. Villafuerte |
Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
|
|
FR2802814B1
(fr)
*
|
1999-12-23 |
2002-02-22 |
Aventis Pharma Sa |
Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
|
|
EP1145717B1
(en)
|
2000-04-13 |
2004-05-12 |
Pfizer Products Inc. |
Synergistic effect of glyburide and milrinone
|
|
GB0014969D0
(en)
*
|
2000-06-19 |
2000-08-09 |
Smithkline Beecham Plc |
Novel method of treatment
|
|
KR200249057Y1
(ko)
*
|
2001-03-22 |
2001-10-19 |
김진환 |
뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
|
|
US6492339B1
(en)
|
2001-05-23 |
2002-12-10 |
Insmed, Incorporated |
Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
|
|
SE0101982D0
(sv)
*
|
2001-06-01 |
2001-06-01 |
Astrazeneca Ab |
Pharmaceutical combination
|
|
US7785627B2
(en)
*
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
|
US9060941B2
(en)
*
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
|
CN100544717C
(zh)
|
2002-09-20 |
2009-09-30 |
华生制药公司 |
含有双胍和噻唑烷二酮衍生物的药物剂型
|
|
US7959946B2
(en)
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
|
US8084058B2
(en)
|
2002-09-20 |
2011-12-27 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
|
US20040147564A1
(en)
*
|
2003-01-29 |
2004-07-29 |
Rao Vinay U. |
Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
|
|
ES2556244T3
(es)
|
2003-10-31 |
2016-01-14 |
Takeda Pharmaceutical Company Limited |
Preparación sólida que comprende pioglitazona, glimepirida y un éster de ácido graso de polioxietilensorbitán
|
|
MXPA04009236A
(es)
*
|
2004-09-23 |
2006-03-27 |
Jorge Luis Rosado Loria |
Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
|
|
WO2006074278A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Mitsunori Ono |
Compositions for treating diabetes or obesity
|
|
TW200722088A
(en)
*
|
2005-05-27 |
2007-06-16 |
Sankyo Co |
Diabetes remedy
|
|
EP1937716A2
(en)
*
|
2005-09-08 |
2008-07-02 |
Uutech Limited |
Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
|
|
US20090170762A1
(en)
*
|
2005-09-08 |
2009-07-02 |
Uutech Limited |
Treatment of Diabetes Related Obesity
|
|
WO2007059372A2
(en)
*
|
2005-11-09 |
2007-05-24 |
St. Jude Children's Research Hospital |
Use of chloroquine to treat metabolic syndrome
|
|
MXPA05013220A
(es)
*
|
2005-12-06 |
2007-06-05 |
Leopoldo De Jesus Espinosa Abdala |
Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
|
|
ES2576258T3
(es)
|
2005-12-22 |
2016-07-06 |
Takeda Pharmaceutical Company Limited |
Preparación sólida que contiene un sensibilizador de insulina
|
|
TW200816995A
(en)
*
|
2006-08-31 |
2008-04-16 |
Daiichi Sankyo Co Ltd |
Pharmaceutical composition containing insulin sensitizers
|
|
AU2008232937B2
(en)
|
2007-03-30 |
2012-09-27 |
Ambrx, Inc. |
Modified FGF-21 polypeptides and their uses
|
|
JP5812318B2
(ja)
|
2007-12-04 |
2015-11-11 |
レメディー ファーマシューティカルズ， インコーポレイテッド |
凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物
|
|
FR2928836B1
(fr)
*
|
2008-03-21 |
2011-08-26 |
Servier Lab |
Forme galenique secable permettant une liberation modifiee du principe actif
|
|
KR20200022525A
(ko)
*
|
2008-12-04 |
2020-03-03 |
충시 위 |
고투과력을 가진 조성물 및 이의 적용
|
|
US20110065756A1
(en)
*
|
2009-09-17 |
2011-03-17 |
De Taeye Bart M |
Methods and compositions for treatment of obesity-related diseases
|
|
CN102655866B
(zh)
*
|
2009-11-13 |
2013-11-13 |
东丽株式会社 |
糖尿病的治疗或预防药
|
|
EP2575826B1
(en)
|
2010-05-24 |
2019-07-17 |
Ozstar Therapeutics Pty Ltd |
Anti-diabetic compositions
|
|
EP4282363A3
(en)
|
2011-01-19 |
2024-01-10 |
Fractyl Health, Inc. |
Devices for the treatment of tissue
|
|
JP2014533702A
(ja)
*
|
2011-11-23 |
2014-12-15 |
オージースター セラピューティクス プロプライアタリ リミテッド |
改良された相乗作用抗糖尿病組成物
|
|
CN103159651B
(zh)
*
|
2011-12-14 |
2015-06-17 |
安徽贝克联合制药有限公司 |
磺酰脲胍及其制备方法和用途
|
|
WO2015077571A1
(en)
|
2013-11-22 |
2015-05-28 |
Fractyl Laboratories, Inc. |
Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract
|
|
IL296643B1
(en)
|
2012-02-27 |
2024-11-01 |
Fractyl Health Inc |
Heat excision systems, devices and methods for tissue treatment
|
|
WO2013159066A1
(en)
|
2012-04-19 |
2013-10-24 |
Fractyl Laboratories, Inc. |
Tissue expansion devices, system and methods
|
|
EP2879605A4
(en)
|
2012-07-30 |
2016-04-06 |
Fractyl Lab Inc |
ELECTRICITY CONTROL SYSTEMS, DEVICES AND METHOD FOR TREATMENT OF TISSUE
|
|
WO2014026055A1
(en)
|
2012-08-09 |
2014-02-13 |
Fractyl Laboratories Inc. |
Ablation systems, devices and methods for the treatment of tissue
|
|
EP2903626A4
(en)
|
2012-10-05 |
2016-10-19 |
Fractyl Lab Inc |
METHODS, SYSTEMS AND DEVICES FOR CARRYING OUT MULTIPLE TREATMENTS OF A PATIENT
|
|
WO2014197632A2
(en)
|
2013-06-04 |
2014-12-11 |
Fractyl Laboratories, Inc. |
Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
|
|
WO2015038973A1
(en)
|
2013-09-12 |
2015-03-19 |
Fractyl Laboratories, Inc. |
Systems, methods and devices for treatment of target tissue
|
|
US10959774B2
(en)
|
2014-03-24 |
2021-03-30 |
Fractyl Laboratories, Inc. |
Injectate delivery devices, systems and methods
|
|
US11185367B2
(en)
|
2014-07-16 |
2021-11-30 |
Fractyl Health, Inc. |
Methods and systems for treating diabetes and related diseases and disorders
|
|
US9757535B2
(en)
|
2014-07-16 |
2017-09-12 |
Fractyl Laboratories, Inc. |
Systems, devices and methods for performing medical procedures in the intestine
|
|
EP3169260B1
(en)
|
2014-07-16 |
2019-09-25 |
Fractyl Laboratories, Inc. |
System for treating diabetes and related diseases and disorders
|
|
PE20170950A1
(es)
|
2014-10-24 |
2017-07-13 |
Bristol Myers Squibb Co |
Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos
|
|
CN108079000A
(zh)
*
|
2018-02-01 |
2018-05-29 |
湖南博隽生物医药有限公司 |
一种治疗糖尿病的药物组合物及其制备方法
|
|
WO2021102423A1
(en)
*
|
2019-11-22 |
2021-05-27 |
Brown University |
Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
|